美国 · SEC FORM 4
Nuvation Bio Inc.
NUVB · NYSE · CIK 0001811063 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
1 qualifying P purchase group
当前 180 天评分窗口
12 同一窗口内观察到的 Form 4 交易行
4 sales · 7 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-06-09 · Mashal Robert · $118.3K
为什么没有活跃信号？
买入活动存在
近期买入1 qualifying line group(s)
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Sauvage PhilippeChief Financial Officer
○▼○
Wentworth KerryCHIEF REGULATORY OFFICER
○▼
Markel StacyCHIEF PEOPLE OFFICER
○▼
Hattersley GaryCHIEF SCIENTIFIC OFFICER
○▼
Mashal RobertDirector
●
● 买入▼ 卖出○ 其他
—
买方广度与集中度
合资格买方1
买入集中度100%最大买方： Mashal Robert · $118.3K
聚集买入 · 15天1 insider峰值活动： 2026-06-09–2026-06-09
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-06-09 · Mashal Robert.
近期 Form 4 活动
1买入
17卖出
22其他 Form 4 交易行
17SEC 申报 · 365天
买入1 qualifying P line(s) · 180 days
卖出4 sale line(s) · 仅供背景
其他7 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 58,862,812
- 上期报告
- 58,173,586
- 日均成交量
- 4,240,489
- 回补天数
- 13.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Mashal Robert | 买入 (P) | Class A Common Stock | 25,000 | USD 4.73 | USD 118,250 | SEC 申报 ↗ |
| 2025-06-18 | Markel Stacy | 买入 (P) | Class A Common Stock | 10,000 | USD 1.71 | USD 17,100 | SEC 申报 ↗ |
| 2025-06-17 | Sauvage Philippe | 买入 (P) | Class A Common Stock | 4,000 | USD 1.79 | USD 7,160 | SEC 申报 ↗ |
| 2025-06-16 | Wentworth Kerry | 买入 (P) | Class A Common Stock | 50,000 | USD 1.79 | USD 89,740 | SEC 申报 ↗ |
| 2025-06-16 | Sjogren Colleen | 买入 (P) | Class A Common Stock | 50,000 | USD 1.81 | USD 90,500 | SEC 申报 ↗ |
| 2025-06-16 | Sauvage Philippe | 买入 (P) | Class A Common Stock | 3,300 | USD 1.84 | USD 6,072 | SEC 申报 ↗ |
| 2025-06-16 | Hung David | 买入 (P) | Class A Common Stock | 500,000 | USD 1.79 | USD 895,000 | SEC 申报 ↗ |
| 2025-04-07 | Hung David | 买入 (P) | Class A Common Stock | 300,000 | USD 1.63 | USD 489,000 | SEC 申报 ↗ |
| 2025-04-04 | Hung David | 买入 (P) | Class A Common Stock | 200,000 | USD 1.66 | USD 332,000 | SEC 申报 ↗ |
| 2025-04-01 | Mashal Robert | 买入 (P) | Class A Common Stock | 100,000 | USD 1.67 | USD 167,000 | SEC 申报 ↗ |
| 2024-10-08 | Mashal Robert | 买入 (P) | Class A Common Stock | 100,000 | USD 2.20 | USD 220,000 | SEC 申报 ↗ |
| 2024-06-25 | Cui Xiangmin | 买入 (P) | Class A Common Stock | 277,895 | USD 2.97 | USD 825,348 | SEC 申报 ↗ |
| 2024-06-24 | Cui Xiangmin | 买入 (P) | Class A Common Stock | 336,874 | USD 2.98 | USD 1,003,885 | SEC 申报 ↗ |
| 2024-06-21 | Cui Xiangmin | 买入 (P) | Class A Common Stock | 75,411 | USD 3.00 | USD 226,233 | SEC 申报 ↗ |
| 2024-06-20 | Cui Xiangmin | 买入 (P) | Class A Common Stock | 87,715 | USD 2.99 | USD 262,268 | SEC 申报 ↗ |
Form 4 申报证据
40 transaction lines in the latest 365-day window; 126 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary | 卖出 (S) | Class A Common Stock | 100,000 | USD 7.09 | USD 709,000 | SEC 申报 ↗ |
| 2026-08-19 | Hattersley Gary | 期权行权／转换 (M) | Class A Common Stock | 100,000 | USD 1.87 | USD 187,000 | SEC 申报 ↗ |
| 2026-07-15 | Sauvage Philippe | 期权行权／转换 (M) | Class A Common Stock | 40,000 | USD 2.17 | USD 86,800 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary | 卖出 (S) | Class A Common Stock | 100,000 | USD 7.09 | USD 709,000 | SEC 申报 ↗ |
| 2026-08-19 | Hattersley Gary | 期权行权／转换 (M) | Class A Common Stock | 100,000 | USD 1.87 | USD 187,000 | SEC 申报 ↗ |
| 2026-07-15 | Sauvage Philippe | 期权行权／转换 (M) | Class A Common Stock | 40,000 | USD 2.17 | USD 86,800 | SEC 申报 ↗ |
| 2026-06-23 | Wentworth Kerry | 卖出 (S) | Class A Common Stock | 63,000 | USD 6.02 | USD 379,260 | SEC 申报 ↗ |
| 2026-06-23 | Wentworth Kerry | 期权行权／转换 (M) | Class A Common Stock | 63,000 | USD 2.93 | USD 184,590 | SEC 申报 ↗ |
| 2026-06-23 | Sauvage Philippe | 卖出 (S) | Class A Common Stock | 47,668 | USD 6.01 | USD 286,485 | SEC 申报 ↗ |
| 2026-06-23 | Sauvage Philippe | 期权行权／转换 (M) | Class A Common Stock | 47,668 | USD 2.17 | USD 103,440 | SEC 申报 ↗ |
| 2026-06-23 | Markel Stacy | 卖出 (S) | Class A Common Stock | 125,000 | USD 6.03 | USD 753,750 | SEC 申报 ↗ |
| 2026-06-23 | Markel Stacy | 期权行权／转换 (M) | Class A Common Stock | 125,000 | USD 1.83 | USD 229,249 | SEC 申报 ↗ |
| 2026-06-09 | Mashal Robert | 买入 (P) | Class A Common Stock | 25,000 | USD 4.73 | USD 118,250 | SEC 申报 ↗ |
| 2026-04-17 | Wentworth Kerry | 卖出 (S) | Class A Common Stock | 36,750 | USD 5.01 | USD 184,118 | SEC 申报 ↗ |
| 2026-04-17 | Wentworth Kerry | 期权行权／转换 (M) | Class A Common Stock | 36,750 | USD 2.93 | USD 107,678 | SEC 申报 ↗ |
| 2026-04-17 | Liu Dongfang | 卖出 (S) | Class A Common Stock | 50,000 | USD 5.02 | USD 251,000 | SEC 申报 ↗ |
| 2026-04-17 | Liu Dongfang | 期权行权／转换 (M) | Class A Common Stock | 50,000 | USD 1.94 | USD 97,000 | SEC 申报 ↗ |
| 2026-04-06 | Wentworth Kerry | 卖出 (S) | Class A Common Stock | 200,000 | USD 4.52 | USD 904,000 | SEC 申报 ↗ |
| 2026-04-06 | Wentworth Kerry | 期权行权／转换 (M) | Class A Common Stock | 200,000 | USD 1.91 | USD 381,000 | SEC 申报 ↗ |
| 2026-02-27 | Makunje Moses | 奖励／授予 (A) | Class A Common Stock | 50,761 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-01 | Liu Dongfang | 卖出 (S) | Class A Common Stock | 150,000 | USD 7.82 | USD 1,173,000 | SEC 申报 ↗ |
| 2025-12-01 | Liu Dongfang | 期权行权／转换 (M) | Class A Common Stock | 150,000 | USD 2.93 | USD 439,500 | SEC 申报 ↗ |
| 2025-11-26 | Liu Dongfang | 卖出 (S) | Class A Common Stock | 10,000 | USD 8.00 | USD 80,000 | SEC 申报 ↗ |
| 2025-11-26 | Liu Dongfang | 期权行权／转换 (M) | Class A Common Stock | 10,000 | USD 3.61 | USD 36,100 | SEC 申报 ↗ |
| 2025-11-25 | Liu Dongfang | 卖出 (S) | Class A Common Stock | 10,000 | USD 7.50 | USD 75,000 | SEC 申报 ↗ |
| 2025-11-25 | Liu Dongfang | 期权行权／转换 (M) | Class A Common Stock | 10,000 | USD 3.61 | USD 36,100 | SEC 申报 ↗ |
| 2025-11-20 | Liu Dongfang | 卖出 (S) | Class A Common Stock | 20,000 | USD 7.00 | USD 140,000 | SEC 申报 ↗ |
| 2025-11-20 | Liu Dongfang | 期权行权／转换 (M) | Class A Common Stock | 20,000 | USD 1.87 | USD 37,400 | SEC 申报 ↗ |
| 2025-11-20 | Hattersley Gary | 卖出 (S) | Class A Common Stock | 369,051 | USD 7.23 | USD 2,668,239 | SEC 申报 ↗ |
| 2025-11-20 | Hattersley Gary | 期权行权／转换 (M) | Class A Common Stock | 369,051 | USD 1.90 | USD 702,149 | SEC 申报 ↗ |
| 2025-11-19 | Hanley David C. | 卖出 (S) | Class A Common Stock | 200,000 | USD 7.14 | USD 1,428,000 | SEC 申报 ↗ |
| 2025-11-19 | Hanley David C. | 期权行权／转换 (M) | Class A Common Stock | 200,000 | USD 1.87 | USD 374,000 | SEC 申报 ↗ |
| 2025-11-19 | Liu Dongfang | 卖出 (S) | Class A Common Stock | 15,000 | USD 5.10 | USD 76,500 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NUVB |
| CIK | 0001811063 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 126 transaction lines from 2020-02-10 to 2026-08-19 41 P purchase lines · 29 S sale lines · 56 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.